Ustekinumab is associated with rapid and sustained clinical effect in the treatment of patients with Crohn’s disease, with additional support for potential mucosal healing, according to a recent review and expert opinion. Based on available evidence for the use of ustekinumab in the treatment of Crohn’s disease, the review determined:

• Ustekinumab had a favorable safety profile, lack of immunogenicity, and the presence of systemic anti-inflammatory activity.
• Ustekinumab requires only 1 single intravenous administration, while subsequent dosing is administered subcutaneously, with the potential advantages for home-based therapy.
• The dosage of ustekinumab is flexible.
• Ustekinumab may be particularly suitable in patients who present extra-intestinal manifestations of the disease or are at risk of infections.